Regulatory Intelligence15 min read
The U.S. shingles landscape is anchored by a recombinant vaccine with nearly a decade of regulatory history, subsequent indication expansion, postmarketing safety actions, and continued label evolution. Its commercial scale remains substantial in 2026, alongside established antiviral treatment and therapies for postherpetic neuralgia.
Regulatory Intelligence10 min read
FDA approvals specifically addressing nausea and vomiting of pregnancy center on doxylamine succinate plus pyridoxine hydrochloride. The underlying reviews show a statistically significant but modest placebo-adjusted efficacy effect, extensive historical support, and a later formulation approval built primarily through pharmacokinetic bridging rather than a new efficacy trial.
Drug Approvals18 min read
Lumvoa (veligrotug-vvze) becomes the second FDA-approved drug specifically indicated for thyroid eye disease, adding a shorter intravenous course to a market established by teprotumumab. FDA review documents reveal important nuances around dose selection, durability, immunogenicity, safety, manufacturing and the product's competitive position.
Regulatory Strategy12 min read
ER-100 has moved partial epigenetic reprogramming from animal models into a first-in-human trial in glaucoma and NAION. Its development program will test not only whether retinal ganglion cell function can be restored, but also how FDA may evaluate a new therapeutic concept built around rejuvenating injured neurons rather than replacing them.
Regulatory Strategy10 min
Human cartilage grafts span distinct FDA regulatory pathways depending on tissue source, processing, intended use, and cellular characteristics. Allogeneic structural grafts, surgical autografts, and cultured chondrocyte products therefore present materially different regulatory strategies.
Drug Development & Regulatory Strategy14 min read
The approval of Simtriyo expands the ADHD treatment landscape and illustrates how regulatory differentiation increasingly depends on mechanism, formulation design, pediatric evidence, abuse-potential controls, and lifecycle planning.
Clinical Development14 min read
An assessment of FDA approvals since 2020 show that novel clinician-reported outcomes can support primary, secondary, and labeling claims, but only when the endpoint is interpretable in its specific context of use. Five applications illustrate how instrument design, rater standardization, estimands, and fallback evidence shape the regulatory outcome.
Clinical Outcome AssessmentsClinician-Reported OutcomesFDA
Read Brief →Cell and Gene Therapy18 min read
Induced pluripotent stem cell-derived blood stem cells could expand the sources available for hematopoietic transplantation and create a platform for genetic correction. Recent preclinical studies strengthen the rationale for durable and molecularly youthful grafts, while leaving human efficacy, safety, and manufacturability unresolved.
Regulatory Strategy11 min read
Recent FDA approvals show expanding scientific and regulatory flexibility for novel antimicrobials. The harder precedent remains commercial: narrow labels, stewardship-constrained use, and fragile launch economics continue to threaten otherwise valuable products.
Regulatory Strategy18 min read
FDA's RMAT approval record reveals several repeatable evidentiary models, from paired-lesion randomization to natural history controls and response-based accelerated approval. The pathway is most valuable when enhanced FDA interaction is used to resolve product-specific uncertainty rather than to avoid it.
Oncology15 min read
Individualized mRNA vaccines have progressed from demonstrations of immune activation to randomized efficacy testing in resected cancer. Intismeran autogene leads the field, while autogene cevumeran and several early-stage platforms are testing whether the model can extend across tumors and development settings.
Cell and Gene Therapy16 min read
Solid-tumor CAR-T has crossed the regulatory threshold, but the clinical evidence remains uneven. One randomized program shows a real but modest survival gain, while several early programs produce striking responses in small, selected cohorts without yet establishing durable population-level benefit.
